Unum Therapeutics Inc (UMRX) Expected to Post Earnings of -$0.43 Per Share

Wall Street brokerages expect Unum Therapeutics Inc (NASDAQ:UMRX) to post earnings of ($0.43) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Unum Therapeutics’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.60). The business is scheduled to announce its next earnings results on Monday, February 11th.

On average, analysts expect that Unum Therapeutics will report full-year earnings of ($1.56) per share for the current fiscal year, with EPS estimates ranging from ($1.67) to ($1.44). For the next financial year, analysts forecast that the company will post earnings of ($1.55) per share, with EPS estimates ranging from ($1.76) to ($1.42). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings results on Monday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.01. Unum Therapeutics had a negative net margin of 404.34% and a negative return on equity of 382.71%. The company had revenue of $2.04 million during the quarter, compared to the consensus estimate of $2.29 million.

UMRX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Unum Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 30th. Morgan Stanley increased their price target on shares of Unum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, October 11th. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research report on Monday, November 19th. Finally, Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Unum Therapeutics in a research report on Tuesday, September 18th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Unum Therapeutics has an average rating of “Buy” and an average target price of $20.67.

UMRX traded down $0.08 during midday trading on Thursday, reaching $6.32. The company’s stock had a trading volume of 49,914 shares, compared to its average volume of 261,451. Unum Therapeutics has a 1 year low of $6.26 and a 1 year high of $17.66.

In other news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $8.46, for a total value of $97,163.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 34,455 shares of company stock valued at $320,776.

A number of large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in shares of Unum Therapeutics in the 3rd quarter valued at $150,000. Bank of New York Mellon Corp acquired a new position in Unum Therapeutics during the second quarter worth $177,000. Spark Investment Management LLC acquired a new position in Unum Therapeutics during the second quarter worth $186,000. Keybank National Association OH acquired a new position in Unum Therapeutics during the second quarter worth $195,000. Finally, JPMorgan Chase & Co. raised its position in shares of Unum Therapeutics by 2,782.4% in the third quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock valued at $213,000 after buying an additional 20,033 shares during the last quarter. 51.81% of the stock is currently owned by institutional investors.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Featured Article: How dollar cost averaging works

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply